Fund Holdings — SR ONE CAPITAL MANAGEMENT, LP

Total Portfolio Value
$461.38M
Total Bought
$45.83M
Total Sold
$0
Net Transaction
+$45.83M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q1 2025
▲▼
Q2 2025
▲▼
Change
▲▼
Q1 2025
▲▼
Q2 2025
▲▼
Weight (%)
▲▼
Change
▲▼
ORIC Pharmaceuticals, Inc.(ORIC)04,514,929+4,514,929045,8279.93%+45,827
ARS Pharmaceuticals, Inc.(SPRY)4,012,9034,012,903050,48270,02515.18%+19,543
CRISPR Therapeutics AG(CRSP)1,048,9511,048,951035,69651,02111.06%+15,325
Zenas BioPharma, Inc(ZBIO)4,911,5394,911,539038,80147,59310.32%+8,792
Arcellx, Inc.
COMMON STOCK
2,346,6302,346,6300153,939154,52633.49%+587
Oruka Therapeutics, Inc(ORKA)430,330430,33004,4154,8241.05%+409
Oculis Holding AG(OCS)322,500322,50006,1376,2601.36%+123
KALA Bio, Inc.(KALA)598,940598,94003,4322,8510.62%-581
Nkarta, Inc.(NKTX)3,333,3333,333,33306,1335,5331.20%-600
enGene Holdings Inc.
COM
747,750747,75003,3502,7220.59%-628
Design Therapeutics, Inc.(DSGN)6,526,4766,526,476025,19221,9944.77%-3,198
Alumis Inc.1,959,8961,959,896012,0345,8801.27%-6,154
Mineralys Therapeutics Inc.(MLYS)3,127,9333,127,933049,67242,3219.17%-7,351
Page 1 of 1
SR ONE CAPITAL MANAGEMENT, LP — 13F Holdings — Q2 2025 | TickerTrail